207 related articles for article (PubMed ID: 20458542)
1. Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
te Vruchte D; Jeans A; Platt FM; Sillence DJ
J Inherit Metab Dis; 2010 Jun; 33(3):261-70. PubMed ID: 20458542
[TBL] [Abstract][Full Text] [Related]
2. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
Kolter T; Sandhoff K
J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
[TBL] [Abstract][Full Text] [Related]
3. New insights into glycosphingolipid functions--storage, lipid rafts, and translocators.
Sillence DJ
Int Rev Cytol; 2007; 262():151-89. PubMed ID: 17631188
[TBL] [Abstract][Full Text] [Related]
4. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU
PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228
[TBL] [Abstract][Full Text] [Related]
5. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal Glycosphingolipid Storage Diseases.
Breiden B; Sandhoff K
Annu Rev Biochem; 2019 Jun; 88():461-485. PubMed ID: 31220974
[TBL] [Abstract][Full Text] [Related]
7. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
Ashe KM; Bangari D; Li L; Cabrera-Salazar MA; Bercury SD; Nietupski JB; Cooper CG; Aerts JM; Lee ER; Copeland DP; Cheng SH; Scheule RK; Marshall J
PLoS One; 2011; 6(6):e21758. PubMed ID: 21738789
[TBL] [Abstract][Full Text] [Related]
8. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein.
Boland B; Smith DA; Mooney D; Jung SS; Walsh DM; Platt FM
J Biol Chem; 2010 Nov; 285(48):37415-26. PubMed ID: 20864542
[TBL] [Abstract][Full Text] [Related]
9. Lyso-glycosphingolipids: presence and consequences.
van Eijk M; Ferraz MJ; Boot RG; Aerts JMFG
Essays Biochem; 2020 Sep; 64(3):565-578. PubMed ID: 32808655
[TBL] [Abstract][Full Text] [Related]
10. Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB; Zaccariotto E; Cox TM
Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
[TBL] [Abstract][Full Text] [Related]
11. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder.
Liu Y; Wada R; Kawai H; Sango K; Deng C; Tai T; McDonald MP; Araujo K; Crawley JN; Bierfreund U; Sandhoff K; Suzuki K; Proia RL
J Clin Invest; 1999 Feb; 103(4):497-505. PubMed ID: 10021458
[TBL] [Abstract][Full Text] [Related]
12. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
[TBL] [Abstract][Full Text] [Related]
13. MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
Lowe JP; Stuckey DJ; Awan FR; Jeyakumar M; Neville DC; Platt FM; Griffin JL; Styles P; Blamire AM; Sibson NR
NMR Biomed; 2005 Dec; 18(8):517-26. PubMed ID: 16206131
[TBL] [Abstract][Full Text] [Related]
14. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Jeyakumar M; Butters TD; Dwek RA; Platt FM
Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
[TBL] [Abstract][Full Text] [Related]
15. Suppression of NK and CD8
White EJ; Trigatti BL; Igdoura SA
J Neuroimmunol; 2017 May; 306():55-67. PubMed ID: 28385189
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders.
Ryckman AE; Brockhausen I; Walia JS
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961778
[TBL] [Abstract][Full Text] [Related]
17. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium.
Lloyd-Evans E; Morgan AJ; He X; Smith DA; Elliot-Smith E; Sillence DJ; Churchill GC; Schuchman EH; Galione A; Platt FM
Nat Med; 2008 Nov; 14(11):1247-55. PubMed ID: 18953351
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
Boomkamp SD; Rountree JS; Neville DC; Dwek RA; Fleet GW; Butters TD
Glycoconj J; 2010 Apr; 27(3):297-308. PubMed ID: 20186478
[TBL] [Abstract][Full Text] [Related]
19. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator.
Glaros EN; Kim WS; Quinn CM; Wong J; Gelissen I; Jessup W; Garner B
J Biol Chem; 2005 Jul; 280(26):24515-23. PubMed ID: 15890646
[TBL] [Abstract][Full Text] [Related]
20. Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs).
Sandhoff R; Sandhoff K
Adv Neurobiol; 2023; 29():333-390. PubMed ID: 36255681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
